Naltrexone
Formulations: - Parenteral > General injections > IM: 380 mg in vial (extended-release) Oral > Solid > tablet: 50 mg Indications: - Disorders due to use of alcohol Source: EML workbook import

Browse procurement-ready healthcare products from trusted vendors across the Afya Chain marketplace.
Formulations: - Parenteral > General injections > IM: 380 mg in vial (extended-release) Oral > Solid > tablet: 50 mg Indications: - Disorders due to use of alcohol Source: EML workbook import
Formulations: - Oral > Solid: 20 mg (as hydrochloride) Indications: - Generalised anxiety disorder - Panic disorder - Social anxiety disorder - Depressive disorders - Obsessive-compulsive disorder - Palliative care Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) - Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) Indications: - Bacterial meningitis - Inflammatory and other diseases of prostate (severe) - Acute pyelonephritis (severe) - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Bacterial pneumonia (Community-acquired pneumonia - severe) - Peritoneal abscess (mild-moderate) - Peritoneal abscess (severe) - Other specified pneumonia (Hospital-acquired pneumonia) - Peritonitis (mild-moderate) - Peritonitis (severe) - Inflammatory and other diseases of prostate (mild to moderate) - Acute pyelonephritis (mild to moderate) - Sepsis without septic shock - Bacterial infection of joint - Osteomyelitis or osteitis - Bacterial infection of unspecified site Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) - Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial Indications: - Bacterial meningitis - Inflammatory and other diseases of prostate (severe) - Acute pyelonephritis (severe) - Other specified pneumonia (Hospital-acquired pneumonia) - Paratyphoid fever - Typhoid fever - Peritonitis (mild-moderate) - Peritonitis (severe) - Peritoneal abscess (mild-moderate) - Peritoneal abscess (severe) - Gonococcal infection - Endophthalmitis - Bacterial pneumonia (Community-acquired pneumonia - severe) - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Necrotising fasciitis - Inflammatory and other diseases of prostate (mild to moderate) - Acute pyelonephritis (mild to moderate) - Infectious gastroenteritis or colitis without specification of infectious agent - Bacterial infection of joint - Sepsis without septic shock - Osteomyelitis or osteitis - Bacterial infection of unspecified site Alternatives: - metronidazole Source: EML workbook import
Formulations: - Oral > Solid: 300 mg Indications: - Bipolar or related disorders Source: EML workbook import
Indications: - Nausea or vomiting - Palliative care Source: EML workbook import
Formulations: - Oral > Liquid: 5 mg per 5 mL Oral > Solid: 10 mg (scored) (hydrochloride) Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride) - Oral > Liquid: 5 mg per 5 mL Oral > Solid: 10 mg (hydrochloride) Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride) Indications: - Nausea or vomiting - Palliative care Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate) Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate) - Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate) Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate) Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate) Indications: - Nausea or vomiting - Palliative care Source: EML workbook import
Indications: - Nausea or vomiting - Palliative care Source: EML workbook import
Indications: - Nausea or vomiting - Palliative care Source: EML workbook import
Formulations: - Oral > Solid > tablet: 400 mg (chewable, scored) - Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable) Indications: - Lymphatic filariasis - Other specified echinococcosis - Cysticercosis of central nervous system - Trichuriasis - Echinococcosis - Cysticercosis - Enterobiasis - Hookworm diseases - Ascariasis Source: EML workbook import
Formulations: - Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate) Indications: - Lymphatic filariasis Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.